Inhibitors of the anaplastic lymphoma kinase

Expert Opinion on Investigational Drugs

Volumn 21, Issue 7, 2012, Pages 985-994

  Mologni, Luca ^a  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

Author keywords

ALCL; ALK; Lung cancer; Targeted therapy; Tyrosine kinase inhibitors

Indexed keywords

AF 802; ANAPLASTIC LYMPHOMA KINASE; ANTINEOPLASTIC AGENT; AP 26113; ASP 3026; BRENTUXIMAB VEDOTIN; CARBOPLATIN; CISPLATIN; CRIZOTINIB; CYCLOPHOSPHAMIDE; DACOMITINIB; DOCETAXEL; DOXORUBICIN; ERLOTINIB; GEFITINIB; IMATINIB; KETOCONAZOLE; LDK 378; METHOTREXATE; NVP TAE 684; PEMETREXED; PREDNISONE; PROTEIN TYROSINE KINASE INHIBITOR; RIFAMPICIN; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR; VINCRISTINE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; B CELL LYMPHOMA; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER SURGERY; CANCER SURVIVAL; CANCER THERAPY; CARCINOGENESIS; CHROMOSOME TRANSLOCATION; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL (TOPIC); COLORECTAL CARCINOMA; DIARRHEA; DNA SEQUENCE; DRUG DOSAGE FORM COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FATIGUE; GENE EXPRESSION; GENE MUTATION; GENE REARRANGEMENT; GENETIC ASSOCIATION; GLIOBLASTOMA; HISTOPATHOLOGY; HUMAN; HYPOCALCEMIA; HYPOPHOSPHATEMIA; KIDNEY CARCINOMA; LARGE CELL LYMPHOMA; LEUKOPENIA; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MAXIMUM PLASMA CONCENTRATION; MELANOMA; MYELOID LEUKEMIA; MYELOPROLIFERATIVE DISORDER; NAUSEA; NEUROBLASTOMA; NONHODGKIN LYMPHOMA; NONHUMAN; ONCOGENE K RAS; OVARY CARCINOMA; PERIPHERAL EDEMA; PERSONALIZED MEDICINE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PLASMA CELL GRANULOMA; PROTEIN DOMAIN; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SKIN DEFECT; SKIN LYMPHOMA; THYROID CARCINOMA; TREATMENT OUTCOME; VOMITING;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS AS TOPIC; DRUG RESISTANCE, NEOPLASM; HUMANS; LUNG NEOPLASMS; LYMPHOMA, LARGE-CELL, ANAPLASTIC; PROTEIN KINASE INHIBITORS; PYRAZOLES; PYRIDINES; RECEPTOR PROTEIN-TYROSINE KINASES; TREATMENT OUTCOME;

EID: 84862286182     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2012.690031     Document Type: Review

References (84)

1. Iwahara T, Fujimoto J, Wen D, et al. Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system. Oncogene 1997;14:439-49 (Pubitemid 27087107)
2. Morris SW, Kirstein MN, Valentine MB, et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science 1994;263:1281-4. (Pubitemid 24107549)
3. Gaidano G, Dalla-Favera R. editors. Pathobiology of non-Hodgkin lymphomas. Churchill Livingstone; New York, NY: 2000
4. Chiarle R, Voena C, Ambrogio C, et al. The anaplastic lymphoma kinase in the pathogenesis of cancer. Nat Rev Cancer 2008;8:11-23
5. Colleoni GW, Bridge JA, Garicochea B, et al. ATIC-ALK: a novel variant ALK gene fusion in anaplastic large cell lymphoma resulting from the recurrent cryptic chromosomal inversion, inv(2) (p23q35). Am J Pathol 2000;156:781-9 (Pubitemid 30626935)
6. Cools J, Wlodarska I, Somers R, et al. Identification of novel fusion partners of ALK, the anaplastic lymphoma kinase, in anaplastic large-cell lymphoma and inflammatory myofibroblastic tumor. Genes Chromosomes Cancer 2002;34:354-62 (Pubitemid 34787456)
7. Hernandez L, Pinyol M, Hernandez S, et al. TRK-fused gene (TFG) is a new partner of ALK in anaplastic large cell lymphoma producing two structurally different TFG-ALK translocations. Blood 1999;94:3265-8 (Pubitemid 29512738)
8. Lamant L, Dastugue N, Pulford K, et al. A new fusion gene TPM3-ALK in anaplastic large cell lymphoma created by a (1;2)(q25;p23) translocation. Blood 1999;93:3088-95 (Pubitemid 29200802)
9. Lamant L, Gascoyne RD, Duplantier MM, et al. Non-muscle myosin heavy chain (MYH9): a new partner fused to ALK in anaplastic large cell lymphoma. Genes Chromosomes Cancer 2003;37:427-32 (Pubitemid 36775787)
10. Tort F, Pinyol M, Pulford K, et al. Molecular characterization of a new ALK translocation involving moesin (MSN-ALK) in anaplastic large cell lymphoma. Lab Invest 2001;81:419-26 (Pubitemid 32245073)
11. Touriol C, Greenland C, Lamant L, et al. Further demonstration of the diversity of chromosomal changes involving 2p23 in ALK-positive lymphoma: 2 cases expressing alk kinase fused to CLTCL (clathrin chain polypeptide-like). Blood 2000;95:3204-7 (Pubitemid 30321174)
12. Beltran B, Castillo J, Salas R, et al. ALK-positive diffuse large B-cell lymphoma: report of four cases and review of the literature. J Hematol Oncol 2009;2:11
13. Takeuchi K, Soda M, Togashi Y, et al. Identification of a novel fusion, SQSTM1-ALK, in ALK-positive large B-cell lymphoma. Haematologica 2011;96:464-7
14. Delsol G, Lamant L, Mariame B, et al. A new subtype of large B-cell lymphoma expressing the ALK kinase and lacking the 2; 5 translocation. Blood 1997;89:1483-90. (Pubitemid 27097438)
15. Lawrence B, Perez-Atayde A, Hibbard MK, et al. TPM3-ALK and TPM4-ALK oncogenes in inflammatory myofibroblastic tumors. Am J Pathol 2000;157:377-84 (Pubitemid 30627557)
16. Panagopoulos I, Nilsson T, Domanski HA, et al. Fusion of the SEC31L1 and ALK genes in an inflammatory myofibroblastic tumor. Int J Cancer 2006;118:1181-6 (Pubitemid 43185605)
17. Bridge JA, Kanamori M, Ma Z, et al. Fusion of the ALK gene to the clathrin heavy chain gene, CLTC, in inflammatory myofibroblastic tumor. Am J Pathol 2001;159:411-15 (Pubitemid 32751070)
18. Debelenko LV, Arthur DC, Pack SD, et al. Identification of CARS-ALK fusion in primary and metastatic lesions of an inflammatory myofibroblastic tumor. Lab Invest 2003;83:1255-65 (Pubitemid 37140310)
19. Ma Z, Hill DA, Collins MH, et al. Fusion of ALK to the ran-binding protein 2 (RANBP2) gene in inflammatory myofibroblastic tumor. Genes Chromosomes Cancer 2003;37:98-105 (Pubitemid 36417927)
20. Gleason BC, Hornick JL. Inflammatory myofibroblastic tumours: where are we now? J Clin Pathol 2008;61:428-37 (Pubitemid 351518223)
21. Takeuchi K, Soda M, Togashi Y, et al. Pulmonary inflammatory myofibroblastic tumor expressing a novel fusion, PPFIBP1-ALK: reappraisal of anti-ALK immunohistochemistry as a tool for novel ALK fusion identification. Clin Cancer Res 2011;17:3341-8
22. Jazii FR, Najafi Z, Malekzadeh R, et al. Identification of squamous cell carcinoma associated proteins by proteomics and loss of beta tropomyosin expression in esophageal cancer. World J Gastroenterol 2006;12:7104-12 (Pubitemid 44890638)
23. Du XL, Hu H, Lin DC, et al. Proteomic profiling of proteins dysregulated in Chinese esophageal squamous cell carcinoma. J Mol Med (Berl) 2007;85:863-75 (Pubitemid 47077107)
24. Marino-Enriquez A, Ou WB, Weldon CB, et al. ALK rearrangement in sickle cell trait-associated renal medullary carcinoma. Genes Chromosomes Cancer 2011;50:146-53
25. Rottgers S, Gombert M, Teigler-Schlegel A, et al. ALK fusion genes in children with atypical myeloproliferative leukemia. Leukemia 2010;24:1197-200
26. Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007;448:561-6. (Pubitemid 47206930)
27. Togashi Y, Soda M, Sakata S, et al. KLC1-ALK: a novel fusion in lung cancer identified using a formalin-fixed paraffin-embedded tissue only. PLoS One 2012;7:e31323
28. Rikova K, Guo A, Zeng Q, et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 2007;131:1190-203 (Pubitemid 350235027)
29. Takeuchi K, Choi YL, Togashi Y, et al. KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistrybased diagnostic system for ALK-positive lung cancer. Clin Cancer Res 2009;15:3143-9
30. Lipson D, Capelletti M, Yelensky R, et al. Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. Nat Med 2012;18:382-4
31. Takeuchi K, Soda M, Togashi Y, et al. RET, ROS1 and ALK fusions in lung cancer. Nat Med 2012;18:378-81
32. Lin E, Li L, Guan Y, et al. Exon array profiling detects EML4-ALK fusion in breast, colorectal, and non-small cell lung cancers. Mol Cancer Res 2009;7:1466-76.
33. Chen Y, Takita J, Choi YL, et al. Oncogenic mutations of ALK kinase in neuroblastoma. Nature 2008;455:971-4.
34. George RE, Sanda T, Hanna M, et al. Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature 2008;455:975-8
35. Janoueix-Lerosey I, Lequin D, Brugieres L, et al. Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature 2008;455:967-70
36. Mosse YP, Laudenslager M, Longo L, et al. Identification of ALK as a major familial neuroblastoma predisposition gene. Nature 2008;455:930-5
37. Murugan AK, Xing M. Anaplastic thyroid cancers harbor novel oncogenic mutations of the ALK gene. Cancer Res 2011;71:4403-11
38. Wood LD, Parsons DW, Jones S, et al. The genomic landscapes of human breast and colorectal cancers. Science 2007;318:1108-13. (Pubitemid 350134889)
39. Ding L, Getz G, Wheeler DA, et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 2008;455:1069-75
40. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 2011;474:609-15
41. Wei X, Walia V, Lin JC, et al. Exome sequencing identifies GRIN2A as frequently mutated in melanoma. Nat Genet 2011;43:442-6
42. Osajima-Hakomori Y, Miyake I, Ohira M, et al. Biological role of anaplastic lymphoma kinase in neuroblastoma. Am J Pathol 2005;167:213-22 (Pubitemid 40884782)
43. Salido M, Pijuan L, Martinez-Aviles L, et al. Increased ALK gene copy number and amplification are frequent in non-small cell lung cancer. J Thorac Oncol 2011;6:21-7
44. Stachurski D, Miron PM, Al-Homsi S, et al. Anaplastic lymphoma kinase-positive diffuse large B-cell lymphoma with a complex karyotype and Cryptic 3' ALK gene insertion to chromosome 4 q22-24. Hum Pathol 2007;38:940-5 (Pubitemid 46726518)
45. Hudson L, Kulig K, Young D, et al. ALK and cMET expression in Glioblastoma multiforme: implications for therapeutic targeting. Mol Cancer Ther 2011;10:abstract #A42
46. Grzelinski M, Steinberg F, Martens T, et al. Enhanced antitumorigenic effects in Glioblastoma on double targeting of pleiotrophin and its receptor ALK. Neoplasia 2009;11:145-56
47. Powers C, Aigner A, Stoica GE, et al. Pleiotrophin signaling through anaplastic lymphoma kinase is rate-limiting for glioblastoma growth. J Biol Chem 2002;277:14153-8 (Pubitemid 34968027)
48. Cosmic catalogue of somatic mutations in cancer. Available from: http://www. sanger.ac.uk/genetics/cgp/cosmic/
49. I.A.R.C. Globocan 2008.
50. Bekkenk MW, Geelen FA, Van Voorst Vader PC, et al. Primary and secondary cutaneous CD30(+) Lymphoproliferative disorders: a report from the Dutch cutaneous lymphoma group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment. Blood 2000;95:3653-61 (Pubitemid 30412833)
51. Fanin R, Sperotto A, Silvestri F, et al. The therapy of primary adult systemic CD30-positive anaplastic large cell lymphoma: results of 40 cases treated in a single center. Leuk Lymphoma 1999;35:159-69 (Pubitemid 29454413)
52. Deconinck E, Lamy T, Foussard C, et al. Autologous stem cell transplantation for anaplastic large-cell lymphomas: results of a prospective trial. Br J Haematol 2000;109:736-42 (Pubitemid 30609750)
53. Younes A. CD30-targeted antibody therapy. Curr Opin Oncol 2011;23:587-93
54. Younes A, Yasothan U, Kirkpatrick P. Brentuximab vedotin. Nat Rev Drug Discov 2012;11:19-20
55. Reck M. Current approaches in chemotherapy of advanced and metastatic non-small cell lung cancer (NSCLC). Anticancer Res 2005;25:1501-6 (Pubitemid 40896755)
56. Pao W, Chmielecki J. Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. Nat Rev Cancer 2010;10:760-74
57. Cui JJ, Tran-Dube M, Shen H, et al. Structure based drug design of Crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK). J Med Chem 2011;54:6342-63
58. Zou HY, Li Q, Lee JH, et al. An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Res 2007;67:4408-17 (Pubitemid 46815090)
59. Christensen JG, Zou HY, Arango ME, et al. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma. Mol Cancer Ther 2007;6:3314-22.
60. Kwak EL, Camidge DR, Clark J, et al. Clinical activity observed in a phase I dose escalation trial of an oral c-met and ALK inhibitor, PF-02341066. J Clin Oncol 2009;27:3509
61. Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010;363:1693-703.
62. Li C, Alvey C, Bello A, et al. Pharmacokinetics (PK) of Crizotinib (PF-02341066) in patients with advanced non-small cell lung cancer (NSCLC) and other solid tumors. J Clin Oncol 2011;29:e13065
63. Butrynski JE, D'adamo DR, Hornick JL, et al. Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor. N Engl J Med 2010;363:1727-33
64. Gambacorti-Passerini C, Messa C, Pogliani EM. Crizotinib in anaplastic large-cell lymphoma. N Engl J Med 2011;364:775-6.
65. Shaw AT, Yeap BY, Solomon BJ, et al. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol 2011;12:1004-12
66. Crino L, Kim D, Riely GJ, et al. Initial phase II results with Crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC): profile 1005. J Clin Oncol 2011;29:7514
67. Choi YL, Soda M, Yamashita Y, et al. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med 2010;363:1734-9.
68. Doebele RC, Pilling AB, Aisner D, et al. Mechanisms of resistance to Crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clin Cancer Res 2012;18:1472-82.
69. Sasaki T, Koivunen J, Ogino A, et al. A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors. Cancer Res 2011;71:6051-60
70. Sasaki T, Okuda K, Zheng W, et al. The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers. Cancer Res 2010;70:10038-43
71. Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001;293:876-80 (Pubitemid 32743979)
72. Kobayashi S, Boggon TJ, Dayaram T, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005;352:786-92 (Pubitemid 40271173)
73. Bresler SC, Wood AC, Haglund EA, et al. Differential inhibitor sensitivity of anaplastic lymphoma kinase variants found in neuroblastoma. Sci Transl Med 2011;3:108ra14
74. Katayama R, Shaw AT, Khan TM, et al. Mechanisms of acquired Crizotinib resistance in ALK-rearranged lung cancers. Sci Transl Med 2012;4:120ra17
75. Katayama R, Khan TM, Benes C, et al. Therapeutic strategies to overcome Crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK. Proc Natl Acad Sci USA 2011;108:7535-40.
76. Rivera VM, Anjum R, Wang F, et al. Efficacy and pharmacodynamic analysis of AP26113, a potent and selective orally active inhibitor of anaplastic lymphoma kinase (ALK). AACR 2010; 2010. Poster #3623
77. Sakamoto H, Tsukaguchi T, Hiroshima S, et al. CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant. Cancer Cell 2011;19:679-90.
78. Galkin AV, Melnick JS, Kim S, et al. Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK. Proc Natl Acad Sci USA 2007;104:270-5 (Pubitemid 46068021)
79. Li N, Michellys PY, Kim S, et al. Activity of a potent and selective phase I ALK inhibitor LDK378 in naive and Crizotinib-resistant preclinical tumor models. Mol Cancer Ther 2011;10:abstract B232
80. El-Deeb IM, Yoo KH, Lee SH. ROS receptor Tyrosine Kinase: a new potential target for anticancer drugs. Med Res Rev 2011;31:794-818
81. Kuromitsu S, Mori M, Shimada I, et al. Anti-tumor activity of ASP3026, A novel and selective ALK inhibitor [abstract #2821]. Proceedings of the 102nd annual meeting of the American association for cancer research 2011
82. Gambacorti-Passerini C, Antolini L, Mahon FX, et al. Multicenter independent assessment of outcomes in chronic myeloid Leukemia patients treated with Imatinib. J Natl Cancer Inst 103:553-61
83. Benson ES. Leukemia and the Philadelphia chromosome. Postgrad Med 1961;30:A22-A8
84. Zuccotto F, Ardini E, Casale E, et al. Through the "Gatekeeper Door": exploiting the active kinase conformation. J Med Chem 2010;53:2681-94.